| Stage | ABBV | % of rev | BMY | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $17.0B | 100.00% | $13.1B | 100.00% | ABBV ×1.30 |
| Gross profit | $12.4B | 73.03% | $7.4B | 56.35% | ABBV +16.7pp |
| Operating income | $6.4B | 37.86% | $2.8B | 21.75% | ABBV +16.1pp |
| Pre-tax income | $4.3B | 25.18% | $2.5B | 19.40% | ABBV +5.8pp |
| Net income | $3.6B | 21.28% | $2.2B | 16.54% | ABBV +4.7pp |
| Stage | ABBV | BMY | Gap · A − B |
|---|---|---|---|
| Revenue | $17.0B100.00% | $13.1B100.00% | ABBV ×1.30 |
| Gross profit | 73.03%$12.4B | 56.35%$7.4B | ABBV +16.7pp |
| Operating income | 37.86%$6.4B | 21.75%$2.8B | ABBV +16.1pp |
| Pre-tax income | 25.18%$4.3B | 19.40%$2.5B | ABBV +5.8pp |
| Net income |
| 21.28%$3.6B |
| 16.54%$2.2B |
| ABBV +4.7pp |
ABBV · IMNM 10-KMar 3 '26
“To date, we have generated our revenue through a Collaboration and Option Agreement, or the Collaboration Agreement, with AbbVie Global Enterprises Ltd., or AbbVie, which terminated in accordance with its terms in July 2025.”
BMY · IMNM 10-KMar 3 '26
“IPR&D expense for the year ended December 31, 2024 primarily related to the write-off of acquired IPR&D assets acquired from Ayala, Bristol-Myers Squibb Company, Zentalis and others that were determined to have no alternative future use.”
ABBV · CTMX 10-KMar 16 '26
“The Varseta-M payload is a topoisomerase-1 inhibitor licensed from AbbVie (formerly ImmunoGen), tailored to have anti-tumor activity against EpCAM-expressing cancer types.”
BMY · CTMX 10-KMar 16 '26
“Pursuant to the BMS Agreement, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $50.0 million and estimated research and development service fees, and we were initially entitled to receive contingent payments of up to $25.0 million for additional targets and contingent payments for development, regulatory and sales milestones.”